Form 4: DexCom CLO Michael Brown Executes Stock Sale

DexCom Executive Vice President and Chief Legal Officer Michael Jon Brown sold 1,700 shares of common stock under a 10b5-1 trading plan.

Summary

• Michael Jon Brown, EVP and Chief Legal Officer of DexCom, sold 1,700 shares of common stock on April 15, 2026.
• The transaction was executed at a price of $63.04 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 111,204 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and does not indicate a change in corporate strategy or outlook.

Positives

• The sale was conducted via a pre-arranged 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• Continued reliance on equity-based compensation, as evidenced by the 77,603 unvested RSUs held by the executive.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of an insider transaction.

Management Comments

• The transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by C-suite executives are common in the medical technology sector and generally do not signal a change in company fundamentals or negative sentiment regarding future performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at large-cap medical device companies like DexCom to manage personal liquidity.
• The volume of shares sold (1,700) is immaterial relative to the total outstanding shares of DexCom.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Next Steps

• Continued vesting of the 77,603 unvested RSUs through March 2029.

Key Dates

Keywords

DexCom, DXCM, Insider Trading, Form 4, 10b5-1, Executive Compensation